Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 8/20 | 0.40 |
| ▸ | CA12 | O43570 | 7/20 | 0.40 |
| ▸ | CA9 | Q16790 | 6/20 | 0.40 |
| ▸ | CA1 | P00915 | 6/20 | 0.40 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.39 |
| ▸ | FGF1 | P05230 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.36 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.36 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PYGB | P11216 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3948805 | 1.00 | CA2 (0.40) | CA2CA12CA9CA1LGALS3 | |
| SCHEMBL22121795 | 1.00 | CA2 (0.40) | CA2CA12CA9CA1LGALS3 | |
| SCHEMBL8003273 | 1.00 | CA2 (0.40) | CA2CA12CA9CA1LGALS3 | |
| SCHEMBL7049511 | 1.00 | CA2 (0.40) | CA2CA12CA9CA1LGALS3 | |
| SCHEMBL29993884 | 1.00 | CA2 (0.40) | CA2CA12CA9CA1LGALS3 | |
| SCHEMBL1116557 | 1.00 | CA2 (0.40) | CA2CA12CA9CA1LGALS3 | |
| SCHEMBL3653142 | 1.00 | CA2 (0.40) | CA2CA12CA9CA1LGALS3 | |
| SCHEMBL1116556 | 1.00 | CA2 (0.40) | CA2CA12CA9CA1LGALS3 | |
| Sulfuric Acid SCHEMBL14764221 | 0.98 | CA2 (0.39) | CA2CA12CA9CA1LGALS3 | |
| SCHEMBL8201748 | 0.89 | LGALS3 (0.39) | CA2CA12CA9CA1LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263527-A1 | Sulfated Galactans With Antithrombotic Activity, Pharmaceutical Composition, Method for Treating or Prophylaxis of Arterial or Venous Thrombosis, Method of Extraction and Use Thereof | S.A. DELTA DO PRATA (BR) | 2011-10-27 | — | — | US | disclosed |
| EP-2280984-A2 | SULFATED GALACTANS WITH ANTITHROMBOTIC ACTIVITY, PHARMACEUTICAL COMPOSITION, METHOD FOR TREATING OR PROPHYLAXIS OF ARTERIAL OR VENOUS THROMBOSIS, METHOD OF EXTRACTION AND USE THEREOF | S.A. Delta Do Prata (BR) | 2011-02-09 | — | — | EP | disclosed |
| WO-2009137899-A2 | SULFATED GALACTANS WITH ANTITHROMBOTIC ACTIVITY, PHARMACEUTICAL COMPOSITION, METHOD FOR TREATING OR PROPHYLAXIS OF ARTERIAL OR VENOUS THROMBOSIS, METHOD OF EXTRACTION AND USE THEREOF | S.A. DELTA DO PRATA (BR) | 2009-11-19 | — | — | WO | disclosed |
| EP-1654013-A1 | ANTIMICROBIAL MATERIALS | Beiersdorf AG (DE) | 2006-05-10 | — | — | EP | disclosed |
| WO-2004089431-A1 | ANTIMICROBIAL MATERIALS | BEIERSDORF AG (DE) | 2004-10-21 | — | — | WO | disclosed |
| EP-1115748-B1 | CARRAGEENAN COMPOSITIONS, AND PROCESSES FOR THEIR PRODUCTION | CP KELCO APS (DK) | 2004-10-20 | — | — | EP | disclosed |
| WO-2004018606-A1 | ABRASIVE CLEANING PREPARATIONS | BEIERSDORF AG (DE) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263527-A1 | Sulfated Galactans With Antithrombotic Activity, Pharmaceutical Composition, Method for Treating or Prophylaxis of Arterial or Venous Thrombosis, Method of Extraction and Use Thereof | ALG8, SERPINC1, F11 | CA2 825/4885CA12 436/4885CA9 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.